[Form 4] Tenaya Therapeutics, Inc. Insider Trading Activity
Tingley Whittemore, Chief Medical Officer of Tenaya Therapeutics, Inc. (TNYA), reported three separate sales on 08/18/2025 to cover tax withholding for vested restricted stock units. Each sale was executed at a weighted average price of $1.253, with individual trade prices ranging from $1.18 to $1.32. The filings show dispositions of 1,608; 1,608; and 1,837 shares, leaving the reporting person with 176,248; 174,640; and 172,803 shares respectively after each transaction. The filing discloses remaining unvested RSUs that will result in future issuance: 103,132; 98,757; and 93,757 shares referenced in the explanatory footnotes. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Tingley Whittemore, Chief Medical Officer di Tenaya Therapeutics, Inc. (TNYA), ha dichiarato tre vendite separate effettuate il 18/08/2025 per coprire le ritenute fiscali su unità azionarie vincolate (RSU) maturate. Ciascuna vendita è stata eseguita a un prezzo medio ponderato di $1,253, con prezzi unitari compresi tra $1,18 e $1,32. Le comunicazioni indicano la disposizione di 1.608; 1.608; e 1.837 azioni, lasciando al dichiarante rispettivamente 176.248; 174.640; e 172.803 azioni dopo ogni operazione. Il documento segnala inoltre RSU non ancora maturate che daranno luogo a future emissioni: 103.132; 98.757; e 93.757 azioni, come riportato nelle note esplicative. Il Modulo 4 è stato firmato da un procuratore per conto del dichiarante.
Tingley Whittemore, Director Médico de Tenaya Therapeutics, Inc. (TNYA), informó tres ventas separadas el 18/08/2025 para cubrir las retenciones fiscales de unidades restringidas de acciones (RSU) que habían vencido. Cada venta se ejecutó a un precio medio ponderado de $1.253, con precios individuales entre $1.18 y $1.32. Los informes muestran la disposición de 1.608; 1.608; y 1.837 acciones, dejando al informante con 176.248; 174.640; y 172.803 acciones respectivamente después de cada operación. La presentación también revela RSU no devengadas que darán lugar a futuras emisiones: 103.132; 98.757; y 93.757 acciones, según las notas explicativas. El Formulario 4 fue firmado por un apoderado en nombre del informante.
팅글리 휘트모어(Tingley Whittemore) Tenaya Therapeutics, Inc.(TNYA) 최고의료책임자는 2025-08-18에 세금 원천징수를 충당하기 위해 성과가 확정된 제한부 주식단위(RSU)를 매각한 세 건의 거래를 보고했습니다. 각 매도는 가중평균 가격 $1.253에 체결되었고, 개별 거래 가격은 $1.18에서 $1.32 사이였습니다. 제출서류에는 각각 1,608; 1,608; 1,837주의 처분이 기재되어 있으며, 각 거래 후 보고자는 각각 176,248; 174,640; 172,803주를 보유하게 되었습니다. 각주에는 향후 발행될 미확정 RSU 수량이 103,132; 98,757; 93,757주로 기재되어 있습니다. Form 4는 보고자를 대신해 대리인이 서명했습니다.
Tingley Whittemore, Chief Medical Officer de Tenaya Therapeutics, Inc. (TNYA), a déclaré trois ventes séparées le 18/08/2025 pour couvrir les retenues fiscales liées aux unités d'actions restreintes (RSU) acquises. Chaque vente a été réalisée à un prix moyen pondéré de 1,253 $, les prix individuels variant de 1,18 $ à 1,32 $. Les déclarations indiquent la cession de 1 608; 1 608; et 1 837 actions, laissant le déclarant avec respectivement 176 248; 174 640; et 172 803 actions après chaque transaction. Le dépôt révèle également des RSU non acquises qui entraîneront des émissions futures : 103 132; 98 757; et 93 757 actions, mentionnées dans les notes explicatives. Le formulaire 4 a été signé par un mandataire au nom du déclarant.
Tingley Whittemore, Chief Medical Officer von Tenaya Therapeutics, Inc. (TNYA), meldete am 18.08.2025 drei separate Verkäufe zur Deckung der Steuerabzüge für ausgeübte Restricted Stock Units (RSUs). Jeder Verkauf erfolgte zu einem gewogenen Durchschnittspreis von $1,253, die Einzelpreise lagen zwischen $1,18 und $1,32. In den Meldungen sind Abgaben von 1.608; 1.608; und 1.837 Aktien angegeben, womit die meldende Person nach den jeweiligen Transaktionen noch 176.248; 174.640; bzw. 172.803 Aktien hält. Die Einreichung weist außerdem ungefallene RSUs aus, die zu künftigen Zuteilungen führen: 103.132; 98.757; und 93.757 Aktien, wie in den erläuternden Fußnoten angegeben. Das Formular 4 wurde von einem Bevollmächtigten im Namen der meldenden Person unterschrieben.
- Disclosure compliance is complete: transaction dates, amounts, prices, resulting beneficial ownership, and explanatory footnotes are provided
- Remaining RSU entitlements are explicitly disclosed (103,132; 98,757; 93,757 shares) and 6,000 shares from the 2021 ESPP are noted
- Share disposals occurred: total of 5,053 shares sold on 08/18/2025 (1,608 + 1,608 + 1,837), reducing immediate shareholdings
- Weighted average sale price is low ($1.253), indicating proceeds per share at that level (trades ranged $1.18–$1.32)
Insights
TL;DR: Routine tax-withholding sales for vested RSUs; disclosure and timing are standard, not an indicator of atypical trading.
The transactions disclosed are coded as sales to cover tax withholding related to the vesting of restricted stock units awarded on specific prior grant dates. The filing provides the weighted average sale price ($1.253) and a disclosed trade price range ($1.18–$1.32), and undertakes to provide detailed allocation of trades by price on request. Reporting compliance appears complete: transaction dates, amounts, resulting beneficial ownership, and explanatory footnotes are included, and the form is signed by an attorney-in-fact.
TL;DR: Sales are straightforward withholding mechanics tied to multiple RSU vesting events; remaining RSU pools are separately disclosed.
The Form 4 shows three separate dispositions all on the same date, each linked to distinct RSU grant vesting dates (Feb 15, 2023; Feb 23, 2024; Jan 24, 2025). Explanatory footnotes explicitly state the numbers of shares that remain issuable upon future vesting and note participation in the 2021 ESPP (6,000 shares). For stakeholders tracking insider-held equity, the filing clarifies net beneficial ownership after each withholding sale and documents compliance with Section 16 disclosure.
Tingley Whittemore, Chief Medical Officer di Tenaya Therapeutics, Inc. (TNYA), ha dichiarato tre vendite separate effettuate il 18/08/2025 per coprire le ritenute fiscali su unità azionarie vincolate (RSU) maturate. Ciascuna vendita è stata eseguita a un prezzo medio ponderato di $1,253, con prezzi unitari compresi tra $1,18 e $1,32. Le comunicazioni indicano la disposizione di 1.608; 1.608; e 1.837 azioni, lasciando al dichiarante rispettivamente 176.248; 174.640; e 172.803 azioni dopo ogni operazione. Il documento segnala inoltre RSU non ancora maturate che daranno luogo a future emissioni: 103.132; 98.757; e 93.757 azioni, come riportato nelle note esplicative. Il Modulo 4 è stato firmato da un procuratore per conto del dichiarante.
Tingley Whittemore, Director Médico de Tenaya Therapeutics, Inc. (TNYA), informó tres ventas separadas el 18/08/2025 para cubrir las retenciones fiscales de unidades restringidas de acciones (RSU) que habían vencido. Cada venta se ejecutó a un precio medio ponderado de $1.253, con precios individuales entre $1.18 y $1.32. Los informes muestran la disposición de 1.608; 1.608; y 1.837 acciones, dejando al informante con 176.248; 174.640; y 172.803 acciones respectivamente después de cada operación. La presentación también revela RSU no devengadas que darán lugar a futuras emisiones: 103.132; 98.757; y 93.757 acciones, según las notas explicativas. El Formulario 4 fue firmado por un apoderado en nombre del informante.
팅글리 휘트모어(Tingley Whittemore) Tenaya Therapeutics, Inc.(TNYA) 최고의료책임자는 2025-08-18에 세금 원천징수를 충당하기 위해 성과가 확정된 제한부 주식단위(RSU)를 매각한 세 건의 거래를 보고했습니다. 각 매도는 가중평균 가격 $1.253에 체결되었고, 개별 거래 가격은 $1.18에서 $1.32 사이였습니다. 제출서류에는 각각 1,608; 1,608; 1,837주의 처분이 기재되어 있으며, 각 거래 후 보고자는 각각 176,248; 174,640; 172,803주를 보유하게 되었습니다. 각주에는 향후 발행될 미확정 RSU 수량이 103,132; 98,757; 93,757주로 기재되어 있습니다. Form 4는 보고자를 대신해 대리인이 서명했습니다.
Tingley Whittemore, Chief Medical Officer de Tenaya Therapeutics, Inc. (TNYA), a déclaré trois ventes séparées le 18/08/2025 pour couvrir les retenues fiscales liées aux unités d'actions restreintes (RSU) acquises. Chaque vente a été réalisée à un prix moyen pondéré de 1,253 $, les prix individuels variant de 1,18 $ à 1,32 $. Les déclarations indiquent la cession de 1 608; 1 608; et 1 837 actions, laissant le déclarant avec respectivement 176 248; 174 640; et 172 803 actions après chaque transaction. Le dépôt révèle également des RSU non acquises qui entraîneront des émissions futures : 103 132; 98 757; et 93 757 actions, mentionnées dans les notes explicatives. Le formulaire 4 a été signé par un mandataire au nom du déclarant.
Tingley Whittemore, Chief Medical Officer von Tenaya Therapeutics, Inc. (TNYA), meldete am 18.08.2025 drei separate Verkäufe zur Deckung der Steuerabzüge für ausgeübte Restricted Stock Units (RSUs). Jeder Verkauf erfolgte zu einem gewogenen Durchschnittspreis von $1,253, die Einzelpreise lagen zwischen $1,18 und $1,32. In den Meldungen sind Abgaben von 1.608; 1.608; und 1.837 Aktien angegeben, womit die meldende Person nach den jeweiligen Transaktionen noch 176.248; 174.640; bzw. 172.803 Aktien hält. Die Einreichung weist außerdem ungefallene RSUs aus, die zu künftigen Zuteilungen führen: 103.132; 98.757; und 93.757 Aktien, wie in den erläuternden Fußnoten angegeben. Das Formular 4 wurde von einem Bevollmächtigten im Namen der meldenden Person unterschrieben.
FAQ
What transactions did TNYA Chief Medical Officer report on 08/18/2025?
At what price were the TNYA shares sold in the Form 4?
How many shares does the reporting person still beneficially own after these transactions?
Are there additional shares issuable to the reporting person from RSUs or ESPP?
Who signed the Form 4 filing for TNYA?
